What University Medical Center Utrecht does

University Medical Center Utrecht (UMC Utrecht) is one of the largest academic medical centers in the Netherlands, headquartered at Heidelberglaan 100, Utrecht, with 12,000+ employees including the Wilhelmina Kinderziekenhuis (WKZ) pediatric hospital, the Julius Centrum for health sciences and primary care (~700 staff), and ten additional divisions. It integrates tertiary patient care, biomedical research and medical education, functioning as a regional hospital for the Utrecht catchment and as a national and international referral center for rare and complex conditions in oncology, regenerative medicine, immunology, brain health, child health, and cardiovascular medicine.

Its core research and clinical products include patient-derived organoid drug-response profiling co-developed with HUB Organoids (Merck KGaA subsidiary), intranasal mesenchymal stem cell therapy for neonatal brain damage (PASSIoN study), CRISPR/base editing programs under Prof. Sabine Fuchs, liver organoid technology commercialized via HELLO R&D, the wireless optical-link brain-computer interface developed with ABILITY Neurotech, and AI-integrated diagnostics through PathAI (digital pathology), Qure.ai (chest X-ray), Paige (prostate biopsy), and Volta Labs (Oxford Nanopore library prep). It operates fully digital pathology workflows since 2015, has conducted the first BrioVAD artificial heart implantation in Europe (2026), the first hologram-assisted brain surgery in the Netherlands (2025), and the first-in-human personalized mRNA therapy for a metabolic disease (2025).

Revenue is generated primarily through the Dutch DBC (Diagnose Behandelings Combinatie) bundled-payment system negotiated with health insurers, supplemented by competitive research grants (European Commission, NWO, ZonMw; notable awards include €7M RSV/asthma, €6.1M STRATA-FIT, €14.9M PreciseOnco, €50M+ Ombion), medical and healthcare education programs, and philanthropic donations routed through the UMC Utrecht & Wilhelmina Kinderziekenhuis Foundation. UMC Utrecht holds ANBI (public-benefit) status, is governed by a Supervisory and Executive Board under Dutch healthcare governance codes, has no identified parent or equity backing, and operates eight office/R&D locations concentrated at Utrecht Science Park with additional satellites in Zeist and Bilthoven.

Name

University Medical Center Utrecht

Legal name

Universitair Medisch Centrum Utrecht

Website

https://umcutrecht.nl

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

University Medical Center Utrecht is a Dutch academic medical center integrating patient care, biomedical research, and medical education across its main hospital and Wilhelmina Kinderziekenhuis pediatric facility, serving as a regional Utrecht hospital and a national referral center for complex and rare diseases.

Ownership category

akta.pro rank

Product category

Academic Hospital Services

NAICS

General Medical and Surgical Hospitals (62211), Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Offices of Physicians (62111)

SIC

Services-Hospitals (8060), Services-Medical Laboratories (8071), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA)

akta.pro secondary industries

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM), Public Research Universities with Academic Medical Centers (AMCs) (EDAHAAAC), Point-of-Care & Decentralized Trial Testing Services (HLAGAEAK)

Keywords

• Academic hospital services
• Medical research programs
• Clinical patient care
• Medical education training
• Specialized healthcare services

Headquarters

HQ city

Utrecht

HQ country

Netherlands

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales, Others

Revenue model

1. Healthcare Services (Diagnose Behandelings Combinatie - DBC): As a Dutch university medical center, UMC Utrecht generates the majority of its revenue through the Dutch Diagnosis-Treatment Combination (DBC) system, a bundled payment mechanism used in the Netherlands for hospital care. Payments are negotiated with health insurers based on volume and case complexity. As an academic medical center, UMC Utrecht receives additional funding for complex care and teaching.
2. Research Grants and EU Funding: UMC Utrecht secures significant competitive research funding from the European Commission (e.g., €7M RSV/asthma grant, €6.1M STRATA-FIT AI grant), Dutch research councils (NWO, ZonMw including Vici-beurs), and private foundations. Grants fund specific research programs and personnel.
3. Medical Education and Training: As part of its academic mission, UMC Utrecht provides medical education and professional training, generating revenue through educational programs and trainee arrangements with partner institutions.
4. Donations and Philanthropy: Donations to the UMC Utrecht & Wilhelmina Kinderziekenhuis Foundation support specific research projects, patient care facilities, and the purchase of advanced medical equipment. Notable examples include a €300,000 donation for the CLEAR cleft palate speech study.

Pricing tiers

Go-to-market motion2 records

Distribution channels7 records

Marketing channels7 records

Core offering

University Medical Center Utrecht (UMC Utrecht) is a Dutch academic medical center that combines advanced patient care, biomedical research, and medical education. It delivers tertiary and complex specialty hospital services through its main campus and the Wilhelmina Kinderziekenhuis (WKZ) children's hospital, conducts pioneering research in oncology, regenerative medicine, immunology, organoids, brain and child health, and trains the next generation of healthcare professionals in collaboration with Universiteit Utrecht.

Product overview

University Medical Center Utrecht operates as an academic medical center providing healthcare services integrated with research and education. The institution offers a unified portfolio combining direct patient care with advanced diagnostic platforms and AI-enabled tools. Core offerings include specialized clinical programs in areas such as RSV-asthma research and rheumatoid arthritis management, supported by digital pathology solutions (PathAI AISight Dx), AI-powered imaging diagnostics (Qure.ai qXR for chest X-rays, Paige for prostate cancer), and genomic sequencing capabilities (Volta Labs Callisto for Oxford Nanopore). The patient-facing Mijn UMC Utrecht portal provides access to medical records and appointments. The center also conducts research in organoid-based drug testing, brain-computer interfaces, and volumetric bioprinting.

Differentiator

Problem solved

Functional benefit

Brands

• Wilhelmina Kinderziekenhuis (WKZ): Children's hospital (Het Wilhelmina Kinderziekenhuis) operating as part of UMC Utrecht
• Julius Centrum
• Mijn UMC Utrecht
• Wilhelmina Kinderziekenhuis Geboortecentrum

Products and services

• UMC Utrecht Hospital Healthcare Services Comprehensive academic hospital services covering cancer, brain, circulatory health, infection & immunity, and regenerative medicine, delivered at the main campus (Heidelberglaan 100, Utrecht). Includes outpatient clinics, inpatient care, emergency medicine, diagnostic services, surgery, and pharmacy.
• Wilhelmina Kinderziekenhuis (WKZ) Pediatric Hospital Services Specialized pediatric and maternal care including the Wilhelmina Kinderziekenhuis Geboortecentrum (birth center), national expert center for conditions such as 'long gap' esophageal atresie, SMA gene therapy (Zolgensma), MPS 1 newborn screening follow-up, and pediatric cardiac care via the Netwerk Aangeboren Hartafwijkingen.
• Mijn UMC Utrecht Patient Portal Online patient portal enabling patients to view results, manage appointments, conduct e-consults, and access their medical records, integrated with the HiX electronic patient dossier.
• UMC Utrecht Academie Medical Education and Training Medical education and professional training programs including medical student training, residency and specialization, nursing trainee programs, and continuing medical education, delivered jointly with partner higher education institutions and the OOR (Onderwijs- en Opleidingsregio) Utrecht.
• Julius Centrum Health Sciences and Primary Care Research Multidisciplinary scientific research and academic dissemination in cardiovascular health, infectious diseases, cancer, and methodology, including PhD dissertations, research programs, and educational offerings for students and healthcare professionals.

Quantifiable outcome

• In the PASSIoN study, 10 newborns with perinatal brain infarction treated with intranasal mesenchymal stem cells showed 20% cerebral palsy rate vs. 50-70% expected in historical/literature controls; no epilepsy or visual problems developed.
• +4 more outcomes

Named customers15 records

Segments6 records

Ideal customer profiles6 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability12 records

Feature9 records

Partnerships

28 partnerships are on record, tiered core, flagship and minor.

• Volta LabscoreTechnology or Integration · 28 May 2026Volta Labs' DNA Library Preparation Application for Oxford Nanopore Technologies Ligation Sequencing Kit V14 was independently clinically evaluated at UMC Utrecht as part of the Oxford Nanopore Compatible Products Programme. Benchmarks showed up to 120 gigabases output per PromethION flow cell with 99.66% SNV recall, supporting ISO 15189 whole genome sequencing workflows.
• ABILITY NeurotechflagshipStrategic or Co-development Partner · 28 May 2026ABILITY Neurotech (Switzerland) received IMDD approval in the Netherlands to begin the first chronic implantation study of its fully implantable wireless optical-link brain-computer interface (BCI) in ALS patients. The trial is conducted at UMC Utrecht, testing whether the battery-free, minimally invasive device can restore communication in real-world home settings.
• ETH ZurichcoreStrategic or Co-development Partner · 27 May 2026Oksana Dudaryeva, formerly postdoctoral researcher at UMC Utrecht, presented research at AMA: Healthcare 2026 demonstrating volumetric bioprinting combined with phase-separating agents developed in collaboration with ETH Zurich, achieving vascular outgrowth beyond 800 microns vs. previous 200-micron limit.
• CBCT Imaging Standards ConsortiumminorStrategic or Co-development Partner · 19 April 2026UMC Utrecht researchers compared cone-beam CT (CBCT) scans to conventional CT scans for measuring skeletal muscle mass in head and neck cancer patients undergoing radiotherapy, establishing CBCT as reliable (intraclass correlation 0.97-0.99) though conventional CT remains preferred standard.
• PaigecoreTechnology or Integration · 12 April 2026UMC Utrecht and Paige launched the CONFIDENT-Prostate study evaluating how AI can assist pathologists in diagnosing prostate cancer biopsies over 9 months with 90 patients. Testing whether Paige AI technology reduces need for immunohistochemistry (IHC) testing while improving diagnostic efficiency, accuracy, and pathologist confidence.
• HUB Organoids (Merck KGaA subsidiary)flagshipStrategic or Co-development Partner · 1 April 2026Co-authored retrospective validation study with HUB Organoids (subsidiary of Merck KGaA) published in Clinical Cancer Research, demonstrating that patient-derived organoid drug-response profiles show clinically meaningful concordance with actual patient outcomes in metastatic colorectal cancer. Merus's Petosemtamab (MCLA-158), developed using these organoids, received FDA Breakthrough Therapy Designation.
• Philips (PreciseOnco Consortium Coordinator)flagshipStrategic or Co-development Partner · 4 February 2026UMC Utrecht is a member of the PreciseOnco research consortium coordinated by Philips, awarded €14.9M in EU Innovative Health Initiative funding (€23.9M total budget including €9M in-kind contributions) over five years. The consortium conducts five clinical studies in spectral imaging, robotic guidance, electrochemotherapy, and AI-guided integrated technologies for precision cancer care.
• Quantum SurgicalcoreTechnology or Integration · 4 February 2026Member of the PreciseOnco consortium alongside Philips, focusing on precision cancer treatment technologies including robotic guidance.
• IGEAcoreTechnology or Integration · 4 February 2026Member of the PreciseOnco consortium alongside Philips, contributing electrochemotherapy technologies for precision oncology.
• Qure.aicoreTechnology or Integration · 9 December 2025Two Dutch hospitals including UMC Utrecht and Catharina Ziekenhuis integrated Qure.ai's qXR artificial intelligence solution into chest X-ray workflows to detect potentially cancerous lung nodules earlier, flagging subtle nodules that radiologists might miss and reducing variation in referral decisions.
• PathAIflagshipTechnology or Integration · 8 December 2025PathAI partnered with UMC Utrecht to deploy its AISight® Dx digital pathology image management system, enabling UMC Utrecht researchers to evaluate AI algorithms from PathAI and other developers for clinical and research applications including PD-L1, HER2, Ki-67, MASH, and tumor microenvironment analysis. UMC Utrecht transitioned to fully digital pathology in 2015. Data stored entirely within Europe on secure cloud infrastructure.
• Fair TherapeuticscoreStrategic or Co-development Partner · 20 October 2025HIT-CF Consortium (over 500 patients from 16 European countries) reported final results evaluating CFTR-modulator drug combination Dirocaftor-Posenacaftor-Nesolicaftor, showing clinical effects proportional to in-vitro responses and supporting biomarker-driven treatment approaches for cystic fibrosis.
• Ombion Centrum voor Proefdiervrije Biomedische Translatie (National Growth Fund)flagshipStrategic or Co-development Partner · 8 July 2025UMC Utrecht coordinates ALS and cystic fibrosis transition projects within Ombion CPBT (National Growth Fund initiative, €50M+ program) involving 60+ partners including universities, companies, regulatory bodies, and patient organizations. UMC Utrecht also contributes to osteoarthritis/rheumatoid arthritis and asthma/COPD projects. The center develops human-relevant disease models without animal testing, accelerating drug development.
• NANOSPRESSO Device ConsortiumcoreStrategic or Co-development Partner · 26 June 2025Researchers developed NANOSPRESSO prototype device enabling hospital pharmacists to produce personalized gene medicines on-site for patients with rare diseases using microfluidics technology to assemble lipid nanoparticles delivering tailored nucleic acids.
• Prinses Máxima CentrumflagshipStrategic or Co-development PartnerOne of six hospitals at Utrecht Science Park on 1.5 km². UMC Utrecht collaborates extensively with Prinses Máxima Centrum (pediatric oncology) on shared research and clinical programs including fungal infection diagnostics and stem cell transplantation for metabolic diseases.
• Diakonessenhuis UtrechtcoreChannel Partner/ Reseller/ DistributorRegional collaboration with Diakonessenhuis Utrecht in patient care (including the 1-2-3-buikportaal for gastrointestinal patient triage), capacity management, and birth care coordination. One of several regional hospital partnerships.
• Alexander Monro BorstkankerziekenhuiscoreStrategic or Co-development PartnerRegional breast cancer care collaboration as part of UMC Utrecht's regional healthcare partnerships.
• Hubrecht InstituteflagshipStrategic or Co-development PartnerWorld-class research institute located at Utrecht Science Park, one of the global leaders in stem cell research. Key research partner for organoid technology and regenerative medicine collaborations with UMC Utrecht.
• Westerdijk InstituutcoreStrategic or Co-development PartnerWorld-class research institute at Utrecht Science Park with the largest fungal collection in the world. Partner for advanced diagnostic and microbiome research.
• RIVM and TNOcoreStrategic or Co-development PartnerNational research institutions at Utrecht Science Park contributing to public health research, infectious disease monitoring, and technological innovation partnerships.
• Genmab, Merus, GenDx, Danone Nutricia Research, Bilthoven BiologicalscoreStrategic or Co-development PartnerInnovative R&D companies in Life Sciences & Health sector at Utrecht Science Park. UMC Utrecht collaborates with these companies on research, clinical trials, and technology transfer.
• Universiteit UtrechtflagshipStrategic or Co-development PartnerPrimary academic partner for medical education, research, and clinical training. Founding partner of Ombion CPBT and key collaborator in EWUU alliance. UMC Utrecht academics hold chairs at and collaborate closely with Universiteit Utrecht.
• Hogeschool Utrecht and ROC Midden NederlandcoreStrategic or Co-development PartnerUMC Utrecht Academie collaborates with these higher education institutions for healthcare professional training and education programs.
• Centraal Militair Hospitaal (CMH)coreStrategic or Co-development PartnerCollaboration through IDR (Instituut Samenwerking Defensie en Relatieziekenhuizen), Civil-Military Centre of Expertise for Trauma Care (CETC), and digital data exchange. CMH patients access UMC Utrecht patient portal (MijnCMH.nl).
• Expoints B.V. / GHX EuropeminorChannel Partner/ Reseller/ DistributorGHX Europe serves as UMC Utrecht's procure partner for electronic order management. Goods delivered to UMC Utrecht locations with digital order receipt confirmation.
• Julius CentrumflagshipStrategic or Co-development PartnerOne of eleven divisions of UMC Utrecht, Julius Centrum is a knowledge center for Health Sciences and Primary Care with ~700 researchers, educators, and support staff. It operates at Utrecht Science Park and in Zeist, conducting multidisciplinary research in cardiovascular health, infectious diseases, cancer, and methodology.
• Wilhelmina Kinderziekenhuis (WKZ)flagshipStrategic or Co-development PartnerWKZ is the pediatric hospital of UMC Utrecht, providing comprehensive children's healthcare. Together with Prinses Máxima Centrum, WKZ has a joint program for children with metabolic diseases. WKZ is part of the Netwerk Aangeboren Hartafwijkingen (Congenital Heart Defects Network).
• Utrecht Science Park FoundationcoreStrategic or Co-development PartnerFoundation representing partners of Utrecht Science Park, promoting joint marketing, community building, events, lobby, acquisition, and quality of life. Partners include Universiteit Utrecht, Hogeschool Utrecht, UMC Utrecht, Prinses Máxima Centrum, RIVM, Nutricia Danone, Genmab, Merus, Bilthoven Biologicals, and regional government bodies.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Hubrecht Institute: The Hubrecht Institute is a leading developmental biology and stem cell research institute co-located at Utrecht Science Park. It is both a research partner and ecosystem neighbor that contributes to UMC Utrecht's organoid and regenerative medicine leadership, including the technology behind HUB Organoids.
• Princess Máxima Center for Pediatric Oncology: Prinses Máxima Centrum is a Dutch national pediatric oncology center also located at Utrecht Science Park. It is a close research and clinical collaborator with UMC Utrecht's WKZ, particularly for hematopoietic stem cell transplantation, fungal infection diagnostics, and metabolic disease programs.

Direct peers

• Radboud University Medical Center: Radboudumc is a Dutch university medical center with similar patient care, research, and education functions. Overlaps with UMC Utrecht in infectious disease, immunology, and rare disease research, and competes for the same NWO and EC grants.
• Maastricht UMC+: Maastricht UMC+ is the southern Dutch university medical center, offering similar academic tertiary care and research. Comparable in mission and structure; competes for clinical referrals and EU research funding.
• Leiden University Medical Center (LUMC): LUMC is another Dutch academic medical center combining tertiary care, biomedical research, and teaching. Comparable in academic profile, specialty focus areas, and funding model, and competes in the same Dutch UMC alliance network.
• Erasmus MC: Erasmus MC is the largest university medical center in the Netherlands, also integrating patient care, research, and education. Both are Dutch UMCs competing for the same EU research grants, top talent, and complex care referrals, making it the most directly comparable peer.
• Amsterdam UMC: Amsterdam UMC was formed from the merger of AMC and VUmc, creating a Dutch UMC of comparable scale and scope. It directly competes with UMC Utrecht for research funding, specialist referrals, and biopharma partnerships in oncology, neurology, and rare diseases.

Broad incumbents

• Karolinska University Hospital: Karolinska University Hospital is affiliated with Karolinska Institutet and is one of Europe's leading academic medical centers. Comparable in integrating research, education, and complex care, and a natural partner/competitor in pan-European research consortia.
• Charité - Universitätsmedizin Berlin: Charité is one of Europe's largest university hospitals and a joint institution of Freie Universität and Humboldt-Universität Berlin. Comparable as a major European AMC partnering with biotech/pharma and running large EU-funded research programs, though at significantly greater scale than UMC Utrecht.

Others

• Philips Research (Health): Philips is the coordinator of the PreciseOnco consortium in which UMC Utrecht participates with €14.9M IHI funding. As a global health technology vendor and Utrecht Science Park partner, Philips is comparable as a strategic enabling partner for UMC Utrecht's precision oncology and AI imaging programs rather than a direct competitor.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/UMCUtrecht
• YouTubeyoutube.com/channel/UCw5hneAhHLz3MGlSNcKjl9A
• Facebookfacebook.com/UMCUtrecht
• LinkedInlinkedin.com/company/umc-utrecht
• Instagraminstagram.com/umcutrecht

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about University Medical Center Utrecht